{
  "id": 5095451,
  "title": "Johnson and Johnson stock hits all-time high at 276.5 USD",
  "url": "https://urgent.news/2026/09/02/johnson-and-johnson-stock-hits-all-time-high-at-276-5-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T13:34:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/johnson-and-johnson-stock-hits-alltime-high-at-2765-usd-93CH-4886280"
  },
  "original_language": "en",
  "account": "Johnson and Johnson's stock price has reached an all-time high of $276.50, just 1% below its 52-week peak of $276.47. This milestone represents a remarkable 55.73% total return for investors over the past year, despite analysts suggesting the stock may be overvalued relative to its Fair Value. The healthcare giant continues its tradition of a $1.09 quarterly dividend, now offered for an impressive 56 consecutive years. With a market cap of $660 billion and a P/E ratio of 31.38, Johnson and Johnson maintains investor confidence in its market strategies and growth potential. As the company navigates the dynamic healthcare landscape, this record-breaking stock price signals a strong market position and a promising future outlook. Analyst firms have offered positive assessments, with UBS raising its price target to $320, Guggenheim to $287, and Raymond James to $280, all with Buy ratings. These upgrades are driven by recent positive developments such as FDA approval of Johnson & Johnson's Ottava robotic surgery platform. However, Medtronic's market position remains neutral according to Piper Sandler, citing its expected leadership in PFA catheters and mapping. Morgan Stanley also highlighted a 1.5% year-over-year growth in US prescription drug sales for the week ending July 31, underscoring ongoing industry shifts.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Replimune Group stock hits 52-week high at 16.2 USD",
        "url": "https://urgent.news/2026/09/02/replimune-group-stock-hits-52-week-high-at-16-2-usd",
        "published": "2026-09-02T13:37:26.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}